Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Zinacef for Meconium-Stained Amniotic Fluid at Term
NCT06849037Recruiting
- Sponsor
- Galilee Medical Center
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in meconium-stained amniotic fluid (MSAF) and chorioamnionitis (IAI) comparing Zinacef treatment with Placebo control (2 arms). Primary endpoint: Peripartum infections at 7 days. Started Feb 2025; status: recruiting.
02
Drugs
cefuroxime
03
Conditions
meconium-stained amniotic fluid (MSAF)chorioamnionitis (IAI)
Beyond the preview
Go deeper on NCT06849037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849037.